International
The Morning Science

What science found today

‹
 

Research

CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial

BioPharma Dive · By Ben Fidler ·

The Brief

  • CG Oncology reported that its therapy cretostimogene cut the risk of recurrence by 68% when given after surgery in a key bladder cancer trial.
  • The results were reported as far exceeding Wall Street's expectations and lifted the company's shares.
  • The source describes the results as 'exceptional'.

Why it matters

The trial reports a large reduction in bladder cancer recurrence after surgery, which could shape how adjuvant treatment is evaluated for this disease.

Who’s affected

  • bladder cancer patients and clinicians
  • investors following biotechnology companies

CG’s therapy cretostimogene cut the risk of recurrence by 68% when administered after surgery, far surpassing Wall Street’s expectations and lifting company shares.

Timeline

  1. BioPharma Dive reports CG Oncology's trial results showing a 68% reduction in recurrence risk

  2. BioPharma Dive - Latest News

    CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial

How do you feel about this?

0 Comments

    CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial – The Morning Science